Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

A 2 arm, 90 patient (45 per cohort) trial in patients with breast cancer who will be
undergoing mastectomy with immediate tissue-expander reconstruction to determine whether
treatment with zafirlukast (20mg PO BID) can reduce or prevent the development of capsular
contracture.

Patients will be block randomized 1:1 into two cohorts: treatment with zafirlukast and the
standard of care, or standard of care alone. Patients will begin treatment with zafirlukast
on post-operative day one following placement of tissue expander(s) once determined safe from
a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice
per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving
radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is
equivalent to 5 half-lives of the drug. Patients will be seen every 1-2 weeks for expander
fill, and will be assessed clinically based on the Baker classification system of capsular
contracture at every appointment. The day of surgery for their expander-implant exchange,
their Baker classification will also be noted.

During expander-implant exchange, three representative sections of the expander capsule will
be collected: medial, lateral and anterior capsule specimens. These specimens will be
bisected; half will be sent to pathology and half will be collected by the Munster lab. Gross
and microscopic determination of capsule thickness will be performed by the pathology
department. The Munster lab will fix and stain the tissues to look for the presence of
collagen, level of fibrosis and number of myofibroblasts. Fibrosis level and collagen
presence will be determined by performing immunohistochemistry with a Trichrome stain of the
tissues, as well as Western blot analysis with Collagen-1. Myofibroblasts will be detected
using immunohistochemistry with commercially available antibodies.

Inclusion Criteria:

1. Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with
immediate placement of tissue expanders and have a strong family history or hereditary
cancer

2. Age ≥ 18 years

3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials
in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus
are unknown. For this reason, women of child-bearing potential must agree to use
adequate contraception: 2 methods of birth control, prior to study entry ad for the
duration of study participation. Should a woman become pregnant or suspect she is
pregnant while she is participating in this study, she should inform her treating
physician immediately.

4. Ability to understand a written informed consent document, and the willingness to sign
it

5. At least 4 weeks post-completion of chemotherapy

6. Adequate organ function within 14 days start of study start:

1. Absolute neutrophil count (ANC) ≥ 1.5 X 10^9/L

2. Hemoglobin (Hgb) ≥9g/dL

3. Platelets (plt) ≥ 100 x 10^9/L

4. Potassium within normal range, or correctable with supplements;

5. AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is
present;

6. Serum total bilirubin ≤ 1.5 x ULN

7. Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min

Exclusion Criteria:

1. Any significant medical condition, laboratory abnormalities, which places the subject
at unacceptable risk if he/she were to participate in the study

2. Currently on a leukotriene inhibitor or used within the past 6 months

3. Prior chest wall radiation

4. Pregnant or breastfeeding

5. Hepatic impairment as defined by:

• AST(SGOT) > 2.5X institutional ULN and ALT(SGPT) > 2.5X institutional ULN

6. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.